L3VLUP
ProSign in

DNA · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DNAGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DNA
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterDNAGILD
Q3 2020none listed holders, n.a.25 holders, $14.2bn
Q4 2020none listed holders, n.a.27 holders, $13.4bn
Q1 2021none listed holders, n.a.24 holders, $14.5bn
Q2 2021none listed holders, n.a.18 holders, $14.9bn
Q3 2021none listed holders, n.a.20 holders, $16.4bn
Q4 2021none listed holders, n.a.20 holders, $16.8bn
Q1 2022none listed holders, n.a.28 holders, $13.2bn
Q2 2022none listed holders, n.a.26 holders, $13.6bn
Q3 2022none listed holders, n.a.24 holders, $13.3bn
Q4 2022none listed holders, n.a.32 holders, $21.1bn
Q1 2023none listed holders, n.a.27 holders, $21.8bn
Q2 2023none listed holders, n.a.24 holders, $20.7bn
Q3 2023none listed holders, n.a.24 holders, $20.0bn
Q4 2023none listed holders, n.a.22 holders, $21.5bn
Q1 2024none listed holders, n.a.30 holders, $20.3bn
Q2 2024none listed holders, n.a.28 holders, $18.5bn
Q3 20245 holders, $62m29 holders, $24.2bn
Q4 20244 holders, $72m28 holders, $25.9bn
Q1 20254 holders, $43m33 holders, $32.0bn
Q2 20254 holders, $80m27 holders, $30.9bn
Q3 20255 holders, $104m23 holders, $29.4bn
Q4 20254 holders, $52m25 holders, $34.3bn
Q1 20262 holders, $37m25 holders, $38.5bn
Q2 20263 holders, $61m26 holders, $34.2bn
DNA

Ginkgo Bioworks Holdings Inc

Holders
4
Reported value
$43m
Buyers
1
Sellers
1

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
33
Reported value
$32.0bn
Buyers
21
Sellers
12

Breadth +9 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DNA (3)

Baillie Gifford & Co, Glenview Capital Management LLC, Viking Global Investors LP

Only GILD (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →